Latest news with #MichaelCurran
Yahoo
25-03-2025
- General
- Yahoo
Oregon sends crew to help battle North Carolina wildfires
PORTLAND, Ore. (KOIN) — Twenty-six Oregon firefighters were sent by the Oregon Department of Forestry to help battle the wildfires in North Carolina. According to the Oregon Department of Forestry, most of the 26 firefighters as well as two agency representatives, arrived in North Carolina and are currently helping the Black Cove fire. In 2024, officials said that North Carolina sent almost an entire incident management team to assist in Oregon and this is Oregon's chance to return the favor. Hillsboro Police release name of man arrested in seven-hour standoff 'Being able to have an additional incident management team made it so we did not have to make the hard choice of prioritizing one fire over another,' said Blake Ellis, Fire Operations Manager. 'At the time, we had two fires in need of an IMT and only one ODF team available. We were able to fill both incidents' needs due to the extra support from our North Carolina partners.' Oregon is part of several mutual assistance agreements within the U.S. and with some Northwest Canadian territories, which ODF said helps to create 'a larger, faster, comprehensive fire management system.' 'These agreements help bolster the complete and coordinated fire protection system and create a cache of reciprocal resources for all of us to call on when needed,' Michael Curran, ODF's Fire Protection Division Chief, said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
07-03-2025
- Health
- Yahoo
ImmunoGenesis doses first subject in Phase I/II trial of hypoxia reversal agent
ImmunoGenesis has initiated the first subject dosing in a multicentre Phase I/II trial of IMGS-101 (evofosfamide), the hypoxia reversal agent, in conjunction with Balstilimab and Zalifrelimab, for treating adults with certain cancer types. The subject was dosed at the University of Texas MD Anderson Cancer Center in Houston, US. The open-label trial will focus on adults with locally advanced or metastatic castration-resistant prostate cancer, human papillomavirus-(HPV) negative squamous cell carcinoma of the head and neck (SCCHN), and pancreatic cancer. It comprises a dose escalation and expansion part to assess the pharmacokinetics, efficacy, anti-tumour activity, and safety of the combination. ImmunoGenesis Clinical Development senior vice-president Dr Charles Schweizer said: 'This trial marks an exciting step forward in addressing one of the key challenges in cancer immunotherapy. Hypoxia limits T-cell infiltration and suppresses immune responses, especially in prostate, pancreatic, and head and neck cancers. 'By reversing hypoxia, IMGS-101 may restore T-cell access to tumours, enhancing the effectiveness of checkpoint inhibitors and potentially transforming outcomes in these hard-to-treat cancers.' Also referred to as Evofosfamide, IMGS-101 is stated to be a 2-nitroimidazole prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM) that was initially developed as a hypoxia-activated prodrug. Dr Michael Curran of MD Anderson and the founder of ImmunoGenesis demonstrated in his lab that IMGS-101 has a unique ability to overcome one of the most significant immunosuppressive barriers by reversing hypoxia. The therapy is claimed to have 'restored' the function of T-cells in pre-clinical models and during a Phase I study, highlighting the early signs of synergy with checkpoint inhibitors. IMGS-101 is being developed as a hypoxia-reversal agent aimed at conditioning tumours to respond to checkpoint inhibition. Balstilimab and Zalifrelimab, both developed by the immuno-oncology company Agenus, are a fully human monoclonal immunoglobulin G1 targeting programmed cell death protein 1 (PD-1) and a cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), respectively. "ImmunoGenesis doses first subject in Phase I/II trial of hypoxia reversal agent" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
